Skip To Main Content
Chris Ehrlich on Muck Rack

Chris Ehrlich

Nashville
As seen in: Datamation, Substack, CMSWire, WXMI-TV (Grand Rapids, MI), TechnologyAdvice, WSYM-TV (Lansing, MI), Reworked, Channel Insider, Enterprise Storage Forum, Enterprise Apps Today, Clinical Leader and
Covers:  artificial intelligence (AI), business, B2B technologies
Author of Parts of a Life: 40 Stories on Youth to Adulthood | Husband | Dad of 3 | Tennis Hacker | @DenisonU

Get in touch with Chris

Contact Chris, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Chris Ehrlich’s Biography

Read Full Bio →

Chris Ehrlich is an award-winning journalist with over 20 years of experience in journalism and content, covering artificial intelligence (AI), business, B2B technologies, and more. His versatile writing has appeared in over 20 media outlets, including Datamation, Reworked, CMSWire, Enterprise Storage Forum, Channel Insider, Portland Business Journal, Grand Rapids Business Journal, The Oregonian, and San Francisco Chronicle.

Chris has been a featured podcast and Twitter chat expert with high-te…

Articles

From "Live Drug" To Precision Tool: Redefining CAR T Safety

|
By Chris Ehrlich
| Drug Discovery Online
By Chris Ehrlich, CEO, CERo Therapeutics In the last decade, CAR T cell therapy has shifted from an experimental moonshot to a cornerstone of modern oncology. By retargeting T cells, the immune system’s high-octane infantry, to recognize cancer with surgical precision, oncology treatment has seen unprecedented remissions in patients who had previously exhausted all options. However, this potency has historically come with a significant tax in the form of systemic toxicity.
Open in Who Shared Issue with article?

From "Live Drug" To Precision Tool: Redefining CAR T Safety

|
By Chris Ehrlich
| Cell & Gene Verified
By Chris Ehrlich, CEO, CERo Therapeutics In the last decade, CAR T cell therapy has shifted from an experimental moonshot to a cornerstone of modern oncology. By retargeting T cells, the immune system’s high-octane infantry, to recognize cancer with surgical precision, oncology treatment has seen unprecedented remissions in patients who had previously exhausted all options. However, this potency has historically come with a significant tax in the form of systemic toxicity.
Open in Who Shared Issue with article?

Overcoming Cell Therapy Design Challenges To Treat ALS And Other Life-Threatening Diseases

|
By Chris Ehrlich
| Clinical Leader Verified
By Chris Ehrlich, CEO, CERo Therapeutics From its conceptualization in the 1980s, the clinical trial landscape for cell-based therapies has had challenges. Personalized, living therapies require a nontraditional clinical trial design, and at the outset of 2025, CERo Therapeutics began a Phase 1 trial of CER-1236, a genetically-engineered, multifunctional T cell that functions at the interface of the innate and adaptive immune systems.
Open in Who Shared Issue with article?
See all 985 articles

Awards

Alliance of Area Business Publishers

2016 - Best Specialty Enewsletter (silver), Best Daily Email (bronze)
View Award